Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Non-Current Debt (2019 - 2025)

BioCorRx (BICX) has disclosed Non-Current Debt for 9 consecutive years, with $69803.0 as the latest value for Q3 2025.

  • Quarterly Non-Current Debt changed N/A to $69803.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $69803.0 through Sep 2025, changed N/A year-over-year, with the annual reading at $71029.0 for FY2024, N/A changed from the prior year.
  • Non-Current Debt hit $69803.0 in Q3 2025 for BioCorRx, down from $71029.0 in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $74300.0 in Q4 2021 to a low of $69803.0 in Q3 2025.
  • Historically, Non-Current Debt has averaged $72245.5 across 4 years, with a median of $72439.5 in 2022.
  • Biggest YoY gain for Non-Current Debt was 0.61% in 2022; the steepest drop was 0.61% in 2022.
  • Year by year, Non-Current Debt stood at $74300.0 in 2021, then fell by 0.61% to $73850.0 in 2022, then decreased by 3.82% to $71029.0 in 2024, then decreased by 1.73% to $69803.0 in 2025.
  • Business Quant data shows Non-Current Debt for BICX at $69803.0 in Q3 2025, $71029.0 in Q4 2024, and $73850.0 in Q4 2022.